Abstract: Performance anomalies in autonomous vehicle can be difficult to identify, and the impact of such anomalies on systems within the autonomous vehicle may be difficult to understand. In examples, systems of the autonomous vehicle are modeled as nodes in a probabilistic graphical network. Probabilities of data generated at each of the nodes is determined. The probabilities are used to determine capabilities associated with higher level functions of the autonomous vehicle.

Abstract: In an aspect a system for loading and securing a payload in an electrical vertical take-off and landing (eVTOL) aircraft may comprise a fuselage further comprising structural elements configured to provide physical support for the aircraft fuselage. An eVTOL aircraft may also comprise a swing nose, where a portion of the nose of the aircraft may swing on a hinge in a radial direction orthogonal to the longitudinal axis of the aircraft. The hinge may be coupled to at least a portion of the fuselage and at least a portion of the nose of the aircraft. A latching mechanism may be configured to secure a payload in an aircraft fuselage. A conveyor mechanism may be configured to transport a payload into the fuselage from the opening of the aircraft.

Abstract: This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3?,4?,5?-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).

Abstract: A handle for a handle bar of a wheeled, pedal driven, electrically assisted vehicle. The handle includes: an elongate body having a first end, a second end and an outer surface; a receiving hollow provided within the elongate body for receiving a portion of a handle bar such that the elongate body may surround the portion of the handle bar, and the outer surface encircles the portion of the handle bar; a display provided at the outer surface at the first end of the elongate body at a first position; and one or more input devices provided at the outer surface at a second position at an opposite side of the main body relative to the first position.

Abstract: The present disclosure relates generally to an arthropod trapping device, more particularly, to a compact and portable trapping device comprising a housing and an insert.

Abstract: This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3?,4?,5?-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).

Abstract: This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3?,4?,5?-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).

Abstract: A method and an apparatus are disclosed for displaying to a user a transition between a first rendered projection of a first image data and a final rendered projection of a second image data, the method comprising obtaining said first image data and said second image data, each generated by a corresponding 3D scanning device scanning a structure; displaying a first view corresponding to a first rendered projection of said first image data in a given window; obtaining an input from the user, said input being indicative of said final rendered projection of a portion of said second image data and displaying in sequence a plurality of views in the given window, each view corresponding to a different rendered projection of at least one of the first image data and the second image data, wherein the plurality of rendered projections are defined so as to perform a transition between the first rendered projection and the final rendered projection, further wherein the transition enables a sequential display of a contin

Abstract: This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3?,4?,5?-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).

Abstract: This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3?,4?,5?-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).

Abstract: This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3?,4?,5?-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).

Abstract: A method of virtually bonding together at least two physical channels in an optical network terminal (ONT) of a passive optical network (PON) can include receiving, via the ONT, a plurality of frames from a network device, classifying, using a processor of the ONT, the plurality of frames into one of a plurality of services, assigning the service to the at least two physical channels of the ONT, wherein each of the at least two physical channels is associated with a respective laser of the ONT to transmit at a respective wavelength, and transmitting, toward an optical line terminal, the plurality of frames of the service using at least one of the at least two physical channels during an assigned time slot.

Abstract: A method of virtually bonding together at least two physical channels in an optical network terminal (ONT) of a passive optical network (PON) can include receiving, via the ONT, a plurality of frames from a network device, classifying, using a processor of the ONT, the plurality of frames into one of a plurality of services, assigning the service to the at least two physical channels of the ONT, wherein each of the at least two physical channels is associated with a respective laser of the ONT to transmit at a respective wavelength, and transmitting, toward an optical line terminal, the plurality of frames of the service using at least one of the at least two physical channels during an assigned time slot.

Abstract: A method of virtually bonding together at least two physical channels in an optical network terminal (ONT) of a passive optical network (PON) can include receiving, via the ONT, a plurality of frames from a network device, classifying, using a processor of the ONT, the plurality of frames into one of a plurality of services, assigning the service to the at least two physical channels of the ONT, wherein each of the at least two physical channels is associated with a respective laser of the ONT to transmit at a respective wavelength, and transmitting, toward an optical line terminal, the plurality of frames of the service using at least one of the at least two physical channels during an assigned time slot.

Abstract: This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3?,4?,5?-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).

Abstract: Systems and techniques for concurrent optical network terminal simulation are described herein. A data packet may be received by an optical lint terminal. It may be determined that the data packet is associated with an optical network terminal simulation host. The data packet may be modified based on the determination. The modified data packet may be transmitted to a device.

Abstract: A method and a system are disclosed for executing a function using a server, providing at least one processing functionality for processing data, the method comprising receiving, at a client, function arguments using a shell function; providing the received arguments to a function located at the server; obtaining result data from an execution of the function using the received arguments and wherein the shell function comprises a declarative function with corresponding function parameters representative of function parameters of the function; further wherein the declarative function has a corresponding function name mapped to the function.

Abstract: A digital broadcast receiver transmits a request for discovery information to a discovery information server, the request including receiver profile information associated with the current state of the digital broadcast receiver. The server identifies, on the basis of the receiver profile information, additional services that are available over an IP with a digital broadcasting receiver, and transmits discovery information for the additional services to the receiver. Then, the digital broadcast receiver determines a receiver channel number in order to locate the additional service at a channel guide on the basis of the received discovery information and logical channel numbers that are assigned to a plurality of broadcast services by a broadcast provider, and generates a channel guide by including the additional services in the determined receiver channel number and the plurality of broadcast services of the respective receiver channel numbers corresponding to the logical channel numbers.

Abstract: A method includes dynamically varying a data acquisition sample rate between at least two data acquisition sample rates during a contrast enhanced perfusion scan based on a level of contrast in image data generated during the scan. A system includes a computed tomography scanner and a console that controls the scanner based on a scan protocol, wherein the console dynamically varies a data acquisition sample rate of scanner during a contrast enhanced perfusion scan based on a level of contrast in the image data generated during the scan. A method for optimizing dose of a scan includes reducing a data acquisition sampling rate during at least a sub-portion of the scan in which a state of interest is not being scanned.

Abstract: Systems and techniques for concurrent optical network terminal simulation are described herein. A data packet may be received by an optical lint terminal. It may be determined that the data packet is associated with an optical network terminal simulation host. The data packet may be modified based on the determination. The modified data packet may be transmitted to a device.